Evidence map›Paper›PMID 26136413›Full record

ArticleJournal of cachexia, sarcopenia and muscle2015

Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure-relevance of inflammatory cytokines.

Yae Matsuo, Konstanze Gleitsmann, Norman Mangner, Sarah Werner, Tina Fischer, T Scott Bowen, Angela Kricke, Yasuharu Matsumoto, Masahiko Kurabayashi, Gerhard Schuler and 2 more

Abstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed.

  1. Article
  2. Irisin deficiency exacerbates cardiac dysfunction and enhances hemorrhage injury in hemorrhage/resuscitation.American journal of physiology. Regulatory, integrative and comparative physiology · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yae MatsuoDepartment of Cardiology, University Leipzig - Heart Center Leipzig, Leipzig, Germany.
Konstanze GleitsmannDepartment of Cardiology, University Leipzig - Heart Center Leipzig, Leipzig, Germany.
Norman MangnerDepartment of Cardiology, University Leipzig - Heart Center Leipzig, Leipzig, Germany.
Sarah WernerDepartment of Cardiology, University Leipzig - Heart Center Leipzig, Leipzig, Germany.
Tina FischerDepartment of Cardiology, University Leipzig - Heart Center Leipzig, Leipzig, Germany.
T Scott BowenDepartment of Cardiology, University Leipzig - Heart Center Leipzig, Leipzig, Germany.
Angela KrickeDepartment of Cardiology, University Leipzig - Heart Center Leipzig, Leipzig, Germany.
Yasuharu MatsumotoDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masahiko KurabayashiDepartment of Cardiology, Gunma University School of Medicine, Maebashi, Japan.
Gerhard SchulerDepartment of Cardiology, University Leipzig - Heart Center Leipzig, Leipzig, Germany.
Axel LinkeDepartment of Cardiology, University Leipzig - Heart Center Leipzig, Leipzig, Germany.
Volker AdamsDepartment of Cardiology, University Leipzig - Heart Center Leipzig, Leipzig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic heart failure (CHF) is commonly associated with muscle atrophy and increased inflammation. Irisin, a myokine proteolytically processed by the fibronectin type III domain containing 5 (FNDC5) gene and suggested to be Peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α activated, modulates the browning of adipocytes and is related to muscle mass. Therefore, we investigated whether skeletal muscle FNDC5 expression in CHF was reduced and if this was mediated by inflammatory cytokines and/or angiotensin II (Ang-II).

methodsSkeletal muscle FNDC5 mRNA/protein and PGC-1α mRNA expression (arbitrary units) were analysed in: (i) rats with ischemic cardiomyopathy; (ii) mice injected with tumour necrosis factor-α (TNF-α) (24 h); (iii) mice infused with Ang-II (4 weeks); and (iv) C2C12 myotubes exposed to recombinant cytokines or Ang-II. Circulating TNF-α, Ang-II, and irisin was measured by ELISA.

resultsIschemic cardiomyopathy reduced significantly FNDC5 protein (1.3 ± 0.2 vs. 0.5 ± 0.1) and PGC-1α mRNA expression (8.2 ± 1.5 vs. 4.7 ± 0.7). In vivo TNF-α and Ang-II reduced FNDC5 protein expression by 28% and 45%, respectively. Incubation of myotubes with TNF-α, interleukin-1ß, or TNF-α/interleukin-1ß reduced FNDC5 protein expression by 47%, 37%, or 57%, respectively, whereas Ang-II had no effect. PGC-1α was linearly correlated to FNDC5 in all conditions. In CHF, animals circulating TNF-α and Ang-II were significantly increased, whereas irisin was significantly reduced. A negative correlation between circulating TNF-α and irisin was evident.

conclusionA reduced expression of skeletal muscle FNDC5 in ischemic cardiomyopathy is likely modulated by inflammatory cytokines and/or Ang-II via the down-regulation of PGC-1α. This may act as a protective mechanism either by slowing the browning of adipocytes and preserving energy homeostasis or by regulating muscle atrophy.

Indexed as

Angiotensin IIChronics heart failureCytokinesFNDC5IrisinSkeletal muscle

Identifiers

PMID26136413
PMCPMC4435098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.